Cutler Group LP Spring Works Therapeutics, Inc. Call Options Transaction History

Cutler Group LP

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 Apr 19, 2024	BUY	$36.5 - $52.5 $3,650 - $5,250	100 Added 25.0%	500 $4,000
Q4 2023 Jan 18, 2024	BUY	$18.94 - $37.24 $3,788 - $7,448	200 Added 100.0%	400 $3,000
Q3 2023 Nov 07, 2023	SELL	$23.12 - $31.38 $41,616 - $56,484	-1,800 Reduced 90.0%	200 $0
Q2 2023 Jul 18, 2023	BUY	$23.15 - $32.71 $25,465 - $35,981	1,100 Added 122.22%	2,000 $5,000
Q1 2023 May 01, 2023	BUY	$24.97 - $34.05 $2,497 - $3,404	100 Added 12.5%	900 $1,000
Q4 2022 Feb 07, 2023	SELL	$21.73 - $28.72 $152,110 - $201,040	-7,000 Reduced 89.74%	800 $1,000
Q3 2022 Oct 25, 2022	BUY	$24.1 - $39.66 $185,570 - $305,382	7,700 Added 7700.0%	7,800 $32,000
Q2 2022 Aug 04, 2022	SELL	$18.36 - $60.07 $782,136 - $2.56 Million	-42,600 Reduced 99.77%	100 $0
Q1 2022 Apr 14, 2022	BUY	$48.97 - $65.46 $2.09 Million - $2.8 Million	42,700 New	42,700 $79,000

238

69.8M

144K

257K

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.34B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.